ストックスクリーナーアプリを入手
29.27
7.06%
1.945
前日終値:
$27.33
開ける：
$27.15
24時間の取引高:
1.12M
Relative Volume:
0.51
時価総額：
$3.58B
収益：
$59.61M
当期純損益:
$-262.14M
株価収益率:
-7.4681
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
+17.04%
1か月 パフォーマンス:
+41.76%
6か月 パフォーマンス:
+112.65%
1年 パフォーマンス:
+185.74%
1日の値動き範囲:
$27.08
$29.56
1週間の範囲:
$24.82
$29.56
52週間の値動き範囲:
$10.05
$29.56
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
29.25 | 3.35B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.64 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.68 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.20 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.13 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.30 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | 開始されました | Goldman | Neutral |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
| 2022-09-07 | 開始されました | Needham | Buy |
| 2022-03-17 | 開始されました | Goldman | Buy |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | アップグレード | Goldman | Neutral → Buy |
| 2020-10-08 | 開始されました | Truist | Buy |
| 2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 開始されました | Cowen | Outperform |
| 2020-02-25 | 開始されました | Goldman | Neutral |
| 2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Why Arcutis Biotherapeutics Inc. stock appeals to dividend seekersJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
Why Arcutis Biotherapeutics Inc. stock is trending among retail tradersFed Meeting & Weekly High Potential Stock Alerts - newser.com
Why Shares in Arcutis Biotherapeutics Surged Again This Week - Nasdaq
Is Arcutis Biotherapeutics Inc. stock a buy for dividend growthBuy Signal & Comprehensive Market Scan Insights - newser.com
Dir Gilbert Files To Sell 16,532 Of Arcutis Biotherapeutics Inc [ARQT] - TradingView
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis - MSN
What moving averages say about Arcutis Biotherapeutics Inc.July 2025 Reactions & Technical Entry and Exit Alerts - newser.com
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal
Will earnings trigger a reversal in Arcutis Biotherapeutics Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
Historical volatility pattern of Arcutis Biotherapeutics Inc. visualized2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com
Arcutis Biotherapeutics Inc Stock Analysis and ForecastMarket Sentiment Indicators & Double Or Triple Returns - earlytimes.in
Arcutis Biotherapeutics stock hits 52-week high at $27.09 By Investing.com - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - sharewise.com
Krishnamohan Neha sells Arcutis Biotherapeutics (ARQT) stock for $939k By Investing.com - Investing.com South Africa
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Krishnamohan Neha sells Arcutis Biotherapeutics (ARQT) stock for $939k - Investing.com
Dir Krishnamohan Sells 40,504 ($939.5K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView
Arcutis Biotherapeutics stock rises on FDA acceptance of pediatric psoriasis drug - Investing.com
Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve - MarketScreener
FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis - HCPLive
FDA Evaluates Arcutis (ARQT) Application to Expand ZORYVE Use in Young Children - GuruFocus
FDA accepts Arcutis’ application for psoriasis cream in children By Investing.com - Investing.com Canada
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 - The Manila Times
Arcutis Biotherapeutics Announces PDUFA Target Action Date for ZORYVE® Cream 0.3% Indication Expansion in Pediatric Plaque Psoriasis - Quiver Quantitative
Arcutis (NASDAQ: ARQT) sNDA for ZORYVE Cream Accepted, PDUFA June 29 2026 target date - Stock Titan
What’s the recovery path for long term holders of Arcutis Biotherapeutics Inc.Portfolio Return Report & High Accuracy Swing Entry Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock undervalued vs historical averages2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
What the charts say about Arcutis Biotherapeutics Inc. todayEntry Point & AI Forecasted Entry/Exit Points - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to global recession fears2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cuts2025 Geopolitical Influence & Fast Entry Momentum Alerts - newser.com
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Multi asset correlation models including Arcutis Biotherapeutics Inc.July 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
Why Arcutis Biotherapeutics Inc. stock attracts high net worth investorsPortfolio Value Report & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Is Arcutis Biotherapeutics Inc. a candidate for recovery playWall Street Watch & Low Drawdown Trading Strategies - newser.com
Arcutis completes enrollment in infant atopic dermatitis study By Investing.com - Investing.com Nigeria
Executive VP & Chief Commercial Officer Of Arcutis Biotherapeutics Sold 40% Of Their Shares - simplywall.st
Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest - Benzinga
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
0.74%
大文字化:
|
ボリューム (24 時間):